Mistletoe Cancer Therapy: A Natural Supportive Approach by ABNOBA India
Mistletoe cancer therapy, rooted in anthroposophic medicine, is gaining global attention as a complementary treatment for cancer patients. ABNOBA GmbH, a Germany-based pharmaceutical company with a strong research background, is at the forefront of this innovation. With its Indian branch, ABNOBA India, the company is extending its expertise and high-quality mistletoe extract therapies to benefit patients across the region.
Mistletoe (Viscum album) extract has been used for decades in Europe as an adjunct therapy for various types of cancer. Administered via subcutaneous injections, mistletoe therapy is known to enhance the patient’s immune response, improve quality of life, reduce side effects from conventional treatments like chemotherapy and radiation, and potentially contribute to improved survival outcomes. It works by stimulating the immune system, increasing the production of natural killer (NK) cells and cytotoxic T-cells that help in targeting cancer cells.
ABNOBA’s mistletoe preparations are standardized, clinically researched, and manufactured under strict pharmaceutical regulations in Germany. Their formulations are tailored to individual patient needs, making them a preferred choice among integrative oncology practitioners.
In India, where integrative and alternative approaches to healthcare are widely appreciated, ABNOBA India is playing a key role in making scientifically-backed mistletoe therapies accessible. Through medical collaborations and continuous education for healthcare professionals, ABNOBA India is fostering a future where conventional and complementary therapies work hand-in-hand for holistic cancer care.
For more details, visit www.abnoba.in – and explore how nature meets science in cancer support.
Comments
Post a Comment